Literature DB >> 32042619

Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway.

Denzel Zhu1, Emily Barry1, Alexander I Sankin1.   

Abstract

Entities:  

Year:  2019        PMID： 32042619      PMCID： PMC6989863          DOI： 10.21037/tau.2019.10.07

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  21 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  The effectiveness of BCG and interferon against non-muscle invasive bladder cancer: a New Zealand perspective.

Authors:  Toni O'Regan; Michael Tatton; Maryanne Lyon; Jonathan Masters
Journal:  BJU Int       Date:  2015-09-02       Impact factor: 5.588

3.  Bladder cancer: Atezolizumab effective against advanced-stage disease.

Authors:  Peter Sidaway
Journal:  Nat Rev Urol       Date:  2016-03-22       Impact factor: 14.432

4.  Combining epigenetic and immune checkpoint inhibitors in bladder cancer.

Authors:  Clemens Thoma
Journal:  Nat Rev Urol       Date:  2019-09       Impact factor: 14.432

5.  G9a and Glp methylate lysine 373 in the tumor suppressor p53.

Authors:  Jing Huang; Jean Dorsey; Sergei Chuikov; Laura Pérez-Burgos; Xinyue Zhang; Thomas Jenuwein; Danny Reinberg; Shelley L Berger
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

6.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

7.  Activating and inhibitory functions for the histone lysine methyltransferase G9a in T helper cell differentiation and function.

Authors:  Bernhard Lehnertz; Jeffrey P Northrop; Frann Antignano; Kyle Burrows; Sima Hadidi; Sarah C Mullaly; Fabio M V Rossi; Colby Zaph
Journal:  J Exp Med       Date:  2010-04-26       Impact factor: 14.307

8.  Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.

Authors:  Cristina Segovia; Edurne San José-Enériz; Ester Munera-Maravilla; Mónica Martínez-Fernández; Leire Garate; Estíbaliz Miranda; Amaia Vilas-Zornoza; Iris Lodewijk; Carolina Rubio; Carmen Segrelles; Luis Vitores Valcárcel; Obdulia Rabal; Noelia Casares; Alejandra Bernardini; Cristian Suarez-Cabrera; Fernando F López-Calderón; Puri Fortes; José A Casado; Marta Dueñas; Felipe Villacampa; Juan José Lasarte; Félix Guerrero-Ramos; Guillermo de Velasco; Julen Oyarzabal; Daniel Castellano; Xabier Agirre; Felipe Prósper; Jesús M Paramio
Journal:  Nat Med       Date:  2019-07-03       Impact factor: 53.440

9.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Authors:  Padmanee Sharma; Margaret K Callahan; Petri Bono; Joseph Kim; Pavlina Spiliopoulou; Emiliano Calvo; Rathi N Pillai; Patrick A Ott; Filippo de Braud; Michael Morse; Dung T Le; Dirk Jaeger; Emily Chan; Chris Harbison; Chen-Sheng Lin; Marina Tschaika; Alex Azrilevich; Jonathan E Rosenberg
Journal:  Lancet Oncol       Date:  2016-10-09       Impact factor: 41.316

10.  Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

Authors:  Manish R Patel; John Ellerton; Jeffrey R Infante; Manish Agrawal; Michael Gordon; Raid Aljumaily; Carolyn D Britten; Luc Dirix; Keun-Wook Lee; Mathew Taylor; Patrick Schöffski; Ding Wang; Alain Ravaud; Arnold B Gelb; Junyuan Xiong; Galit Rosen; James L Gulley; Andrea B Apolo
Journal:  Lancet Oncol       Date:  2017-12-05       Impact factor: 41.316
View more
  1 in total

Review 1.  Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer.

Authors:  Khyati Meghani; Lauren Folgosa Cooley; Andrea Piunti; Joshua J Meeks
Journal:  Bladder Cancer       Date:  2022-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.